{"disease":{"id":"major-nerve","name":"major nerve"},"drugs":{"marketed":[{"drug_id":"ropivacaine","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Naropin","generic_name":"ROPIVACAINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Amide Local Anesthetic","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"bupivacaine","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"BUPIVACAINE","company_name":"Innocoll","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"Amide Local Anesthetic","quality_score":69,"revenue":null,"mechanism":"Bupivacaine works by blocking nerve impulses to prevent pain signals from reaching the brain."},{"drug_id":"bupivacain","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupivacain","company_name":"Sisli Hamidiye Etfal Training and Research Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ropivacain","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ropivacain","company_name":"University Hospital, Basel, Switzerland","drug_phase":"marketed","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naropine","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropine","company_name":"Rigshospitalet, Denmark","drug_phase":"phase_1","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naropeine","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropeine","company_name":"University Hospital, Rouen","drug_phase":"phase_3","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"levobupivacaine","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chirocain","generic_name":"LEVOBUPIVACAINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"levobupivacaine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bupivacaine-hydrochloride-and-epinephrine","indication_name":"Major Nerve Block for Surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride","generic_name":"Bupivacaine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nerve sodium channels","drug_class":"Amide-type local anesthetic","quality_score":10,"revenue":null,"mechanism":"Bupivacaine blocks nerve impulse generation and conduction by increasing electrical excitation threshold and slowing action potential rise."}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04556877","title":"Different Intra-abdominal Pressures and Optic Nerve Size","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Trakya University","has_results":false},{"nct_id":"NCT07385430","title":"Study of LGW16-03 To Identify Nerves","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Eric R. Henderson","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}